{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:18:25Z","timestamp":1773753505749,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The effect of antiviral therapy in chronic hepatitis B (CHB) on reducing the risk of long-term complications (LTCs) remains unclear so far. To study whether long-term nucleos(t)ide analogues therapy can reduce the risk of long-term complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched MEDLINE, EMBASE, OVID, the Cochrane Central Register of Controlled Trials. Relative risks (RRs) of long-term complications with or without treatment were studied. Also subgroup analyses including the status of drug-resistance, HBeAg and pre-existing compensated cirrhosis were done using relative risks of long-term complications either with or without treatment or among nucleos(t)ide analogues treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six eligible studies (3644 patients in all) were included. Data showed the incidence of long-term complications in treatment groups was induced by 74%(RR:0.26, 95% CI: 0.15-0.47) compared with no treatment. Whether drug-resistant happened or not during the long-term therapy, the incidence of long-term complications was still significantly induced respectively by 45%(RR: 0.55,95%CI:0.40-0.76) and 78% (RR:0.22, 95%CI: 0.13-0.36). For both different status of HBeAg and pre-existing compensated cirrhosis, there was significant lower incidence of long-term complications in treatment groups compared with no treatment, too. Moreover, among the NA treatment groups, patients with drug-resistance had 2.64 times (RR:2.64, 95%CI: 1.58-4.41) higher chance of developing to long-term complications, and patients with pre-existing compensated cirrhosis also had 3.07 times (RR:3.07, 95%CI: 1.04-9.11) higher chance of developing to long-term complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Long-term nucleos(t)ide analogue therapy for adults with CHB prevents or delays the development of long-term complications including decompensated cirrhosis, CHB-related death or CHB-related HCC in patients with CHB. The patients who need take antiviral drugs should receive the antiviral therapy as soon as possible.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1743-422x-8-72","type":"journal-article","created":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T20:09:31Z","timestamp":1297886971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Long-Term Nucleos(t)ide Analogues Therapy for Adults With Chronic Hepatitis B reduces the Risk of Long-Term Complications: a meta-analysis"],"prefix":"10.1186","volume":"8","author":[{"given":"Qin-Qin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huai-Dong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,15]]},"reference":[{"key":"1179_CR1","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","volume":"337","author":"WM Lee","year":"1997","unstructured":"Lee WM: HBV infection. N Engl J Med 1997, 337: 1733-1745. 10.1056\/NEJM199712113372406","journal-title":"N Engl J Med"},{"key":"1179_CR2","first-page":"2971","volume-title":"Fields Virology","author":"FB Hollinger","year":"2001","unstructured":"Hollinger FB, Liang TJ: Hepatitis B Virus. In Fields Virology. 4th edition. Edited by: Knipe DM, Howley PM. Philadelphia, Lippincott Williams & Wilkins; 2001:2971-3036.","edition":"4"},{"key":"1179_CR3","first-page":"545","volume":"54","author":"M Saoleas","year":"2007","unstructured":"Saoleas M, Lygidakis NJ, Manti C: Hepatitis B today. Hepatogastroenterology 2007, 54: 545-548.","journal-title":"Hepatogastroenterology"},{"key":"1179_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/hep.1840080310","volume":"8","author":"YF Liaw","year":"1988","unstructured":"Liaw YF, Tai DI, Chu CM, Chen TJ: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8: 493-6. 10.1002\/hep.1840080310","journal-title":"Hepatology"},{"key":"1179_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/gut.32.3.294","volume":"32","author":"G Fattovich","year":"1991","unstructured":"Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, Ruol A: Natural history and prognostic factors for chronic hepatitis type B. Gut 1991, 32: 294-8. 10.1136\/gut.32.3.294","journal-title":"Gut"},{"key":"1179_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.7326\/0003-4819-101-5-613","volume":"101","author":"JI Weissberg","year":"1984","unstructured":"Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, Robinson WS, Merigan TC, Gregory PB: Survival in chronic hepatitis B: an analysis of three hundred seventy-nine patients. Ann Intern Med 1984, 101: 613-6.","journal-title":"Ann Intern Med"},{"key":"1179_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, REVEAL-HBV Study Group: Risk of hepatocellular carcinoma across a biological gradient of serum HBV DNA level. JAMA 2006, 295: 65-73. 10.1001\/jama.295.1.65","journal-title":"JAMA"},{"key":"1179_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130: 678-686. 10.1053\/j.gastro.2005.11.016","journal-title":"Gastroenterology"},{"issue":"2","key":"1179_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/hep.21513","volume":"45","author":"AS Lok","year":"2007","unstructured":"Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007,45(2):507-39. 10.1002\/hep.21513","journal-title":"Hepatology"},{"issue":"2","key":"1179_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009,51(2):237-67. 10.1016\/j.jhep.2009.04.009","journal-title":"J Hepatol"},{"issue":"3","key":"1179_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1440-1746.2003.03037.x","volume":"18","author":"YF Liaw","year":"2003","unstructured":"Liaw YF, Leung N, Guan R, Lau GK, Merican I: Asian-Pacific consensus statement on the management of Chronic hepatitis B: an update. J Gastroenterol Hepatol 2003,18(3):239-45. 10.1046\/j.1440-1746.2003.03037.x","journal-title":"J Gastroenterol Hepatol"},{"key":"1179_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/gast.2003.50013","volume":"124","author":"JL Dienstag","year":"2003","unstructured":"Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER: Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124: 105-17. 10.1053\/gast.2003.50013","journal-title":"Gastroenterology"},{"key":"1179_CR13","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131: 1743-51. 10.1053\/j.gastro.2006.09.020","journal-title":"Gastroenterology"},{"issue":"2","key":"1179_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1056\/NEJM199807093390201","volume":"339","author":"CL Lai","year":"1998","unstructured":"Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998,339(2):61-8. 10.1056\/NEJM199807093390201","journal-title":"N Engl J Med"},{"issue":"17","key":"1179_CR15","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","volume":"341","author":"JL Dienstag","year":"1999","unstructured":"Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999,341(17):1256-63. 10.1056\/NEJM199910213411702","journal-title":"N Engl J Med"},{"issue":"5","key":"1179_CR16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0168-8278(99)80123-8","volume":"30","author":"Y Suzuki","year":"1999","unstructured":"Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K: Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999,30(5):743-8. 10.1016\/S0168-8278(99)80123-8","journal-title":"J Hepatol"},{"issue":"3","key":"1179_CR17","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/hep.22414","volume":"48","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008,48(3):750-8. 10.1002\/hep.22414","journal-title":"Hepatology"},{"issue":"5","key":"1179_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/jac\/dkl551","volume":"59","author":"E William","year":"2007","unstructured":"William E, Delaney : Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother 2007,59(5):827-32. 10.1093\/jac\/dkl551","journal-title":"J Antimicrob Chemother"},{"key":"1179_CR19","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/sim.4780071202","volume":"7","author":"RJ Ozminkowski","year":"1988","unstructured":"Ozminkowski RJ, Wortman PM, Roloff DW: Inborn\/outborn status and neonatal survival: a meta-analysis of non-randomized studies. Stat Med 1988, 7: 1207-1221. 10.1002\/sim.4780071202","journal-title":"Stat Med"},{"issue":"7","key":"1179_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1445-2197.2007.04141.x","volume":"77","author":"NS Abraham","year":"2007","unstructured":"Abraham NS, Byrne CM, Young JM, Solomon MJ: Meta-analysis of non-randomized comparative studies of the short-term outcomes of laparoscopic resection for colorectal cancer. ANZ J Surg 2007,77(7):508-16. 10.1111\/j.1445-2197.2007.04141.x","journal-title":"ANZ J Surg"},{"key":"1179_CR21","unstructured":"The Cochrane LibraryChichester, UK: JWiley; 2008. [http:\/\/www.cochrane.org]"},{"key":"1179_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7: 177-188. 10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"issue":"15","key":"1179_CR23","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004,351(15):1521-31. 10.1056\/NEJMoa033364","journal-title":"N Engl J Med"},{"issue":"1","key":"1179_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hep.20760","volume":"42","author":"GV Papatheodoridis","year":"2005","unstructured":"Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ: Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005,42(1):121-9. 10.1002\/hep.20760","journal-title":"Hepatology"},{"key":"1179_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.hepres.2005.02.006","volume":"32","author":"A Matsumoto","year":"2005","unstructured":"Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumata H, Omata M, Okita K, Hayashi N, Okanoue T, Lino S, Tanikawa K, The Inuyama Hepatitis Study Group: Efcacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005, 32: 173-84. 10.1016\/j.hepres.2005.02.006","journal-title":"Hepatol Res"},{"key":"1179_CR26","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/135965350701200816","volume":"12","author":"MF Yuen","year":"2007","unstructured":"Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL: Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007, 12: 1295-303.","journal-title":"Antivir Ther"},{"key":"1179_CR27","doi-asserted-by":"publisher","first-page":"664A","DOI":"10.1016\/j.jhep.2006.10.011","volume":"46","author":"JR Eun","year":"2007","unstructured":"Eun JR, Lee HJ, Lee SH, Kim TN, Jang BIK, Choi JW, Park YS, Kim KO, Lee KH, Moon HJ, Lee SH: The effect of lamivudine and adefovir dipivoxil on preventing hepatocellular carcinoma in HBV-related liver cirrhosis. Hepatology 2007, 46: 664A-5A. 10.1016\/j.jhep.2006.10.011","journal-title":"Hepatology"},{"issue":"1","key":"1179_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jhep.2010.02.026","volume":"53","author":"Eun Jong Ryul","year":"2010","unstructured":"Jong Ryul Eun, Heon Ju Lee, Tae Nyeun Kim, Kyeung Soo Lee: Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in HBV-related liver disease. J Hepatol 2010,53(1):118-25. 10.1016\/j.jhep.2010.02.026","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"1179_CR29","first-page":"183","volume":"42","author":"YF Liaw","year":"2005","unstructured":"Liaw YF, Farrell G, Sung JJY, Chow WC, Shue K, Keene ON, Dixon JS: Disease progression in chronic hepatitis B with advanced fibrosis or cirrhosis. J Hepatol 2005,42(Suppl 2):183.","journal-title":"J Hepatol"},{"key":"1179_CR30","doi-asserted-by":"publisher","first-page":"262A","DOI":"10.1016\/S0270-9139(03)80263-X","volume":"38","author":"YF Liaw","year":"2003","unstructured":"Liaw YF, Sung JJY, Chow WC, Shue K, Keene O, Farrel G: Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial. Hepatology 2003, 38: 262A-3A. 10.1016\/S0270-9139(03)80263-X","journal-title":"Hepatology"},{"key":"1179_CR31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2893.2009.01070.x","volume":"16","author":"Y-F Yang","year":"2009","unstructured":"Yang Y-F, Zhao W, Zhong Y-D, Xia H-M, Shen L, Zhang N: Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. Journal of Viral Hepatitis 2009, 16: 265-27. 10.1111\/j.1365-2893.2009.01070.x","journal-title":"Journal of Viral Hepatitis"},{"key":"1179_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1056\/NEJM199807093390201","volume":"339","author":"CL Lai","year":"1998","unstructured":"Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B: Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998, 339: 61-68. 10.1056\/NEJM199807093390201","journal-title":"N Engl J Med"},{"key":"1179_CR33","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa020681","volume":"348","author":"P Marcellin","year":"2003","unstructured":"Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348: 808-816. 10.1056\/NEJMoa020681","journal-title":"N Engl J Med"},{"issue":"9","key":"1179_CR34","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa021812","volume":"348","author":"SJ Hadziyannis","year":"2003","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Hadziyannis SJ, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003,348(9):800-7. 10.1056\/NEJMoa021812","journal-title":"N Engl J Med"},{"key":"1179_CR35","first-page":"111","volume-title":"Ann Intern Med","author":"TA Shamliyan","year":"2009","unstructured":"Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, Tacklind J, Rutks I, Kane RL, Wilt TJ: Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009, 111-124."},{"issue":"10","key":"1179_CR36","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.cgh.2009.05.025","volume":"7","author":"VW Wong","year":"2009","unstructured":"Wong VW, Wong GL, Chim AM, Choi PC, Chan AW, Tsang SW, Hui AY, Chan HY, Sung JJ, Chan HL: Surrogate end points and long-term outcome in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2009,7(10):1113-20. 10.1016\/j.cgh.2009.05.025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1179_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1053\/j.gastro.2003.10.050","volume":"126","author":"R Perrillo","year":"2004","unstructured":"Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E: Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant HBV. Gastroenterology 2004,126(1):81-90. 10.1053\/j.gastro.2003.10.050","journal-title":"Gastroenterology"},{"key":"1179_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1743-422X-6-163","volume":"6","author":"Chen En-Qiang","year":"2009","unstructured":"En-Qiang Chen, Li-Chun Wang, Jun Lei, Lu Xu, Hong Tang: Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant HBV. Virol J 2009, 6: 163. 10.1186\/1743-422X-6-163","journal-title":"Virol J"},{"key":"1179_CR39","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354: 1001-1010. 10.1056\/NEJMoa051285","journal-title":"N Engl J Med"},{"key":"1179_CR40","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","volume":"133","author":"RG Gish","year":"2007","unstructured":"Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133: 1437-1444. 10.1053\/j.gastro.2007.08.025","journal-title":"Gastroenterology"},{"key":"1179_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/hep.22323","volume":"48","author":"M Sherman","year":"2008","unstructured":"Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R: Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008, 48: 99-108. 10.1002\/hep.22323","journal-title":"Hepatology"},{"key":"1179_CR42","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/hep.20464","volume":"40","author":"F van Bommel","year":"2004","unstructured":"van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, Wiedenmann B, Berg T: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant HBV infection. Hepatology 2004, 40: 1421-1425. 10.1002\/hep.20464","journal-title":"Hepatology"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-8-72.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T07:14:22Z","timestamp":1685949262000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-8-72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,15]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-8-72","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,15]]},"assertion":[{"value":"5 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"72"}}